RBBP7 and neuroblastoma: In the case of neuroblastoma, tumors with high amplification of MYCN show hyperactivation of PRC2-associated components such as EZH2, EED, and RBBP7 with respect to non-MYCN-amplified neuroblastoma cases (Henrich et al., 2016).